Novocure Ltd Stock
Price
Target price
€14.64
€14.64
-2.670%
-0.405
-2.670%
-
18.06.25 / Tradegate
WKN: A140ML / Name: Novocure / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
Novocure Ltd Stock
We can see a decrease in the price for Novocure Ltd. Compared to yesterday it has lost -€0.405 (-2.670%).
Our community identified positive and negative aspects for Novocure Ltd stock for the coming years. 1 users see the criterium "Shareholder structure" as a plus for the Novocure Ltd stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Novocure Ltd in the next few years
Pros
?
S********** s********
?
B****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Novocure Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novocure Ltd | -2.670% | -6.902% | -6.724% | -18.011% | -49.742% | -73.749% | -73.857% |
| Ironwood Pharmaceuticals | 2.520% | 7.965% | 12.963% | -89.107% | -85.476% | -94.374% | -92.781% |
| Arrowhead Pharmaceuticals Inc. | -1.780% | -2.459% | -2.637% | -44.300% | -28.143% | -54.228% | -62.436% |
| Iovance Biotherapeutics Inc. | -0.660% | -11.771% | 10.247% | -77.066% | -75.167% | -81.613% | -93.570% |
News
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society
Novocure Announces Upcoming Investor Events
Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events.
-
PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May 31
Novocure Reports First Quarter 2025 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the first quarter ended March 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive